



February 18, 2015

Pharmacy Announcement

Drug Use Review (DUR) Board Approves Changes to MSM Chapter 1200 Effective January 1, 2015

The Nevada Medicaid Drug Use Review (DUR) Board met on July 24, 2014, and approved changes to clinical criteria for the following medications. Details for these changes can be found in the Nevada Medicaid Services Manual (MSM) Chapter 1200 Prescribed Drugs.

The following changes were effective January 1, 2015:

- **Kalydeco® (Ivacaftor)** – Added seven new gene mutations as qualifiers for coverage.
- **Medications for the Treatment of Acne** – Added criteria for recipients age 21 years or older.
- **Xolair® (Omalizumab)** – Added new diagnosis coverage for chronic idiopathic urticaria.